Cynata Therapeutics Limited
The Carlton-based Cynata Therapeutics Limited (ASX: CYP) is a clinical-stage biotechnology company engaged in developing and commercialising its flagship product Cymerus, based on its proprietary mesenchymal stem cell technology for human therapeutic use in Australia.
Currently, it has a market cap of AUD 179.73 million with ~ 101.55 million outstanding shares. On March 19th, the securities of Cynata Therapeutics were placed in a trading halt until the release of an announcement. The regular trading is expected to commence on Thursday, March 21st, 2019. The CYP last traded at AUD 1.770 on March 18th, 2019. Recently, the company issued around 50,000 fully paid ordinary shares at an issue price of AUD 1.00 per share following the exercise of 50,000 unlisted July 17th, 2020 options. Besides, it also received a favorable advice from the UK’s Medicines and Healthcare products Regulatory Agency for its planned Phase 2 clinical trial of CYP-002 in patients with critical limb ischemia.
The Melbourne-based Mesoblast Limited (ASX: MSB) is a biopharmaceutical company that offers allogeneic cellular medicines. The company has a market of AUD 698.08 million with ~ 498.63 million outstanding shares. On March 19th, at the end of the trading session, the MSB stock price closed at AUD 1.480, up 5.714%, by AUD 0.080 with ~ 2.81 million shares traded. Recently, Mesoblast informed of two upcoming investor conferences where it will be featured. These include the Oppenheimer 29th Annual Healthcare Conference in New York on Wednesday, March 20th, 2019 at 1:00 p.m. ET. And secondly, at The Alliance for Regenerative Medicine’s Seventh Annual Cell & Gene Therapy Investor Day in New York on Thursday, March 21st, 2019 at 4:15 p.m. ET.
The company also released its financial results and operational highlights for the first half ended December 31st, 2018, posting the pro-forma cash at hand of ~ USD 92.0 million. The revenue was also stable at USD 13.5 million, compared with USD 14.6 million in the first half of FY2018. Besides, Mesoblast also completed enrolment in their major cardiovascular Phase 3 trial, executed the cardiovascular partnership in China amongst other activities.
MMJ Group Holdings Limited
The Sydney-based MMJ Group Holdings Limited (ASX: MMJ), established in 2014, is a healthcare company with a portfolio of cannabis sector investments worldwide. To date, MMJ has a market cap of ~ AUD 52.93 million with ~ 230.15 million outstanding shares. With the end of the trading session on March 19th, 2019, the MMJ stock closed at a sell-off price of AUD 0.255, soaring by 10.87%, by AUD 0.025 with ~ 2.48 million shares traded.
On March 19th, 2019, the company released the latest update on the valuation of its investment portfolio, posting its unaudited NTA per share as of February 28th, 2019 at ~ 31 cents, which subsequently increased further by 32% to approximately 41 cents per share as of March 19th, 2019. As per the update, MMJ has liquid funds of $ 7.6 million and more than 80% of its portfolio is held in listed investments. Moreover, Harvest One Cannabis Inc, through its wholly-owned subsidiary United Greeneries Ltd, recently entered into an agreement to become a medical cannabis supplier to Canada-based Shoppers Drug Mart.
Healthscope Limited (ASX: HSO), based in Melbourne, provides healthcare services to patients across New Zealand and Australia. Currently, the company has a large market cap of AUD 4.25 billion with ~ 1.74 billion outstanding shares. With the end of the trading session on March 19th, the HSO stock prices closed at AUD 2.440 with ~ 18.19 million outstanding shares. Also, the HSO stock has generated a positive YTD return of 11.42% so far.
On March 19th, the company announced that the Foreign Investment Review Board had expressed no objection through a written correspondence addressed to Brookfield Business Partners, NorthWest Healthcare and Medical Properties Trust for the proposed full acquisition of Healthscope by Brookfield .The correspondence satisfies all conditions under the Implementation Deed signed between Healthscope and Brookfield. For the 1HFY19, the company reported a 199% rise in the statutory NPAT $ 236.6 million and a 3% increase in the Group’s revenue to $ 1,224.6 million with an operating EBITDA of $ 198.1 million.
The Lane Cove, Australia-based Nanosonics Limited (ASX: NAN), is engaged in the research, and development decontamination products and related technology designed to reduce spread of infection. Currently, the company has a market cap of AUD 1.3 billion with ~ 299.88 million outstanding shares. On March 19th, the NAN stock closed at AUD 4.280, down 1.382%, by AUD 0.060 and ~ 1.02 million shares traded.
Nanosonics released its financial results for the half-year ended December 31st, 2018, posting total revenue at $ 40.7 million, up 36% on the prior corresponding period (pcp) and an operating profit after tax of $ 11.0 million, up 195% on pcp. The company successfully launched its trophon®2 product in North America, Europe and Australia during the period with positive customer reaction. At the end of the half-year, the net cash balance amounted to $ 71.3 million, up $ 1.8 million which is going to support active growth and expansion.
Besides, the global installed base of 19,310 increased by 9% for the half-year and 20% in the last 12 months. Recently, the results of the Japanese study were released, demonstrating significant (90%) ultrasound probe contamination.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.